Search
Karyopharm Therapeutics Inc
KPTIAdd to Watchlist
9.020USD
-0.380-4.04%
Close 06/18, 16:00（ET）Quotes delayed by 15 min
165.17MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-06-18The current earnings forecast score of Karyopharm Therapeutics Inc is 8.29, ranking 44 out of 157 in the Pharmaceuticals industry. The average price target is 15.00, with a high of 21.00 and a low of 6.00.
Analyst Rating
Based on
7
analysts
Buy
Current Rating
13.400
Target Price
+42.55%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
175
Total
6
Median
8
Average
Company name
Ratings
Analysts
Karyopharm Therapeutics Inc
KPTI
7
Amgen Inc
AMGN
38
Biogen Inc
BIIB
38
Eli Lilly and Co
LLY
35
AbbVie Inc
ABBV
34
Vertex Pharmaceuticals Inc
VRTX
34
1
2
3
...
35
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is Karyopharm Therapeutics Inc's expected revenue for the next quarter?
Karyopharm Therapeutics Inc's expected revenue is 33.12M.
What is Karyopharm Therapeutics Inc's price target?
Analysts forecast that Karyopharm Therapeutics Inc's price target is USD 15.00, with the highest forecast at USD 21.00 and the lowest forecast at USD 6.00.
How have Karyopharm Therapeutics IncKPTI's recent earnings per share performed?
The market expectation was USD -1.02, while Karyopharm Therapeutics IncKPTI's earnings per share (EPS) for the previous quarter was USD -5.68. EPS for the next quarter is expected at USD -1.31.
What is the analyst rating for Karyopharm Therapeutics Inc?
Based on the ratings of Karyopharm Therapeutics Inc's stock from 7 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
